Dr Nick Cunniffe

University Position

Clinical Lecturer

Dr Nick Cunniffe is pleased to consider applications from prospective PhD students.

Interests

I am a Clinical Lecturer in Neurology. My research is centred on the different ways of promoting and measuring remyelination in people living with multiple sclerosis; it is anticipated that through enhancing remyelination of damaged nerves we can delay, prevent, or reverse the progression of disability. I work on clinical trials, in particular the Cambridge Centre for Myelin Repair remyelination trials and, at the Cambridge Clinical Vision Laboratory, I use visual evoked potentials (VEP), optical coherence tomography (OCT), and tests of eye movements and visual function to measure the effects of remyelinating and neuroprotective therapies. I am also working to integrate these measures of remyelination and axonal health into routine clinical practice, alongside MRI-based measures. Outside of the lab, I am committed to medical education. I supervise neuroscience to medical students at Gonville and Caius College and am co-author of an undergraduate neuroscience textbook.

Cambridge Clinical Vision Laboratory

Collaborators

Cambridge

Key Publications

Remyelination varies between and within lesions in multiple sclerosis following bexarotene.

DOI: http://doi.org/10.1002/acn3.51662
Journal: Ann Clin Transl Neurol
E-pub date: 1 Oct 2022
Authors: JWL Brown, F Prados, DR Altmann, B Kanber, J Stutters, NG Cunniffe, JL Jones, ZG Georgieva, EJ Needham, C Daruwalla, CG Wheeler-Kingshott, P Connick, S Chandran, R Franklin, D MacManus, R Samson, A Coles, D Chard

Remyelination in humans due to a retinoid-X receptor agonist is age-dependent.

DOI: http://doi.org/10.1002/acn3.51595
Journal: Ann Clin Transl Neurol
E-pub date: 1 Jul 2022
Authors: CE McMurran, T Mukherjee, JWL Brown, AW Michell, DT Chard, RJM Franklin, AJ Coles, NG Cunniffe

Safety and efficacy of bexarotene in patients with relapsing-remitting multiple sclerosis (CCMR One): a randomised, double-blind, placebo-controlled, parallel-group, phase 2a study.

DOI: http://doi.org/10.1016/S1474-4422(21)00179-4
Journal: Lancet Neurol
E-pub date: 1 Sep 2021
Authors: JWL Brown, NG Cunniffe, F Prados, B Kanber, JL Jones, E Needham, Z Georgieva, D Rog, OR Pearson, J Overell, D MacManus, RS Samson, J Stutters, C Ffrench-Constant, CAM Gandini Wheeler-Kingshott, C Moran, PD Flynn, AW Michell, RJM Franklin, S Chandran, DR Altmann, DT Chard, P Connick, AJ Coles

The MS Remyelinating Drug Bexarotene (an RXR Agonist) Promotes Induction of Human Tregs and Suppresses Th17 Differentiation In Vitro.

DOI: http://doi.org/10.3389/fimmu.2021.712241
Journal: Front Immunol
E-pub date: 1 Aug 2021
Authors: CM Gaunt, DB Rainbow, RJ Mackenzie, LB Jarvis, HS Mousa, N Cunniffe, Z Georgieva, JW Brown, AJ Coles, JL Jones

Systematic approach to selecting licensed drugs for repurposing in the treatment of progressive multiple sclerosis.

DOI: http://doi.org/10.1136/jnnp-2020-324286
Journal: J Neurol Neurosurg Psychiatry
E-pub date: 1 Mar 2021
Authors: N Cunniffe, KA Vuong, D Ainslie, D Baker, J Beveridge, S Bickley, P Camilleri, M Craner, D Fitzgerald, AG de la Fuente, G Giovannoni, E Gray, L Hazlehurst, R Kapoor, R Kaur, D Kozlowski, B Lumicisi, D Mahad, B Neumann, A Palmer, L Peruzzotti-Jametti, S Pluchino, J Robertson, A Rothaul, L Shellard, KJ Smith, A Wilkins, A Williams, A Coles

Promoting remyelination in multiple sclerosis.

DOI: http://doi.org/10.1007/s00415-019-09421-x
Journal: J Neurol
E-pub date: 1 Jan 2021
Authors: N Cunniffe, A Coles

Publications

Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis.

DOI: http://doi.org/10.1177/13524585231151951
Journal: Mult Scler
E-pub date: 1 Jun 2023
Authors: C Daruwalla, V Shaygannejad, S Ozakbas, EK Havrdova, D Horakova, R Alroughani, C Boz, F Patti, M Onofrj, A Lugaresi, S Eichau, M Girard, A Prat, P Duquette, B Yamout, SJ Khoury, SA Sajedi, R Turkoglu, A Altintas, O Skibina, K Buzzard, P Grammond, R Karabudak, A van der Walt, H Butzkueven, D Maimone, J Lechner-Scott, A Soysal, N John, J Prevost, D Spitaleri, C Ramo-Tello, O Gerlach, G Iuliano, M Foschi, R Ampapa, V van Pesch, M Barnett, N Shalaby, M D'hooghe, J Kuhle, MJ Sa, M Fabis-Pedrini, A Kermode, S Mrabet, R Gouider, S Hodgkinson, G Laureys, L Van Hijfte, R Macdonell, C Oreja-Guevara, E Cristiano, P McCombe, JL Sanchez-Menoyo, B Singhal, Y Blanco, S Hughes, J Garber, C Solaro, C McGuigan, B Taylor, K de Gans, M Habek, A Al-Asmi, S Mihaela, T Castillo Triviño, T Al-Harbi, JI Rojas, O Gray, D Khurana, B Van Wijmeersch, N Grigoriadis, J Inshasi, J Oh, E Aguera-Morales, Y Fragoso, F Moore, C Shaw, SM Baghbanian, N Shuey, B Willekens, TA Hardy, D Decoo, AP Sempere, D Field, R Wynford-Thomas, NG Cunniffe, I Roos, CB Malpas, AJ Coles, T Kalincik, JWL Brown

Seeing is believing: Identifying remyelination in the central nervous system.

DOI: http://doi.org/10.1016/j.coph.2022.102269
Journal: Curr Opin Pharmacol
E-pub date: 1 Oct 2022
Authors: MFE Hill, NG Cunniffe, RJM Franklin

How achievable are COVID-19 clinical trial recruitment targets? A UK observational cohort study and trials registry analysis.

DOI: http://doi.org/10.1136/bmjopen-2020-044566
Journal: BMJ Open
E-pub date: 5 Oct 2020
Authors: NG Cunniffe, SJ Gunter, M Brown, SW Burge, C Coyle, A De Soyza, T Dymond, H Esmail, DP Francis, J Galloway, JB Galloway, E Gkrania-Klotsas, J Greenaway, G Katritsis, P Kanagaratnam, MD Knolle, K Leonard, ZC McIntyre, B Prudon, T Rampling, ME Torok, B Warne, M Yates, NJ Matheson, L Su, S Villar, GD Stewart, M Toshner

Using saccades to diagnose covert hepatic encephalopathy.

DOI: http://doi.org/10.1007/s11011-014-9647-8
Journal: Metab Brain Dis
E-pub date: 1 Jun 2015
Authors: N Cunniffe, H Munby, S Chan, D Saatci, E Edison, RHS Carpenter, D Massey